Skip to main content
. 2023 Nov 9;29(12):3111–3119. doi: 10.1038/s41591-023-02620-0

Table 4.

Effects of potential confounders and potential modifiers of the risk estimates

All hematological malignancies Lymphoid malignancies Myeloid malignancies
# ERR /100 mGy 95% CI # ERR /100 mGy 95% CI # ERR /100 mGy 95% CI
Main results1 790 1.96 1.10 3.12 578 2.01 1.02 3.42 203 2.02 0.47 4.77
Potential confounders analysis:
No adjustment for birth cohort
790 1.92 1.08 3.05 578 1.99 1.02 3.37 203 1.92 0.43 4.53
a) SES2
Unadjusted 210 1.40 0.08 3.83 161 0.99 −0.16 3.37 47 4.22 −0.17 30.6
Adjusted 210 1.44 0.10 3.90 161 1.03 −0.15 3.45 47 4.16 −0.17 29.6
Effect modification analysis:
a) Sex
Males 466 1.45 0.55 2.80 343 1.91 0.71 3.85 118 0.65 -0.42 2.89
Females 324 2.82 1.27 5.32 235 2.14 0.71 4.64 85 6.09 1.62 19.1
Het. P value 0.20 0.85 0.03
b) Age at exposure category (note: one individual can enter in more than one category if they had several CTs)
<5 219 0.78 0.06 1.78 165 0.74 −0.05 1.93 52 1.12 −0.29 3.60
5 to <10 156 1.81 0.57 3.39 115 1.87 0.48 3.74 40 1.72 −0.71 5.41
10+ 466 4.02 2.48 5.99 336 4.25 2.41 6.71 124 3.48 1.05 7.35
Het. P value 0.001 0.002 0.32
c) Time since exposure (years) (note: one individual can enter in more than one category if they had several CTs)
2 to <5 303 3.56 1.96 5.57 222 3.09 1.37 5.37 76 4.88 1.66 9.87
5 to <10 291 2.82 1.58 4.33 216 2.90 1.46 4.70 74 2.98 0.66 6.40
10+ 260 1.24 0.42 2.29 184 1.46 0.49 2.75 72 0.45 −0.80 2.56
Het. P value 0.07 0.21 0.04

1Stratified on sex, birth cohort and country—attained age is used as the underlying time variable.

2Analysis restricted to countries where SES data were available: Belgium, France, the Netherlands and Spain.

#, number of cases; Het., heterogeneity.